Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
$2.42
-$0.20(-3.17%)
At close: 4:00 PM EST
$2.42
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.05 - $8.00
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$76.36M
Enterprise Value-$56.47M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Mar 26, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding31,555,126
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)11.51
Price to Sales (P/S)0.00
P/FCF Ratio-29.72
Enterprise Value/Market Cap-0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.52
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$10.00Price Target Upside313.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignThe elimination of the pre-treatment biopsy requirement in Arm 3 should meaningfully accelerate screening-to-enrollment conversion rates by reducing patient hesitancy.
Financial ResourcesThe company ended the recent period with $134.4 million in cash and investments, providing sufficient resources to advance its clinical programs.
Strategic DevelopmentManagement is expected to discuss incorporating the BM-agnostic combo arm into ACR-368's confirmatory trial design, a move likely seen as positive for the program.
Bears Say
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $8.00 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $76.36M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 98 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.591 by $0.121.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,555,126 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.591. Following the earnings report the stock price went up 8.213%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (313.22% Upside)
$10.00 (313.22% Upside)
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
-32.32%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. The company leverages its proprietary precision medicine platform to identify patients most likely to benefit from its drug candidates. Acrivon's core products include advanced drug candidates designed to address specific unmet needs in cancer treatment.
ACRV Stock 12 Month Forecast
Average Price Target
$10.00
▲(313.22% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
44.25% Insiders
2.21% Mutual Funds
34.78% Other Institutional Investors
16.27% Public Companies and Individual Investors
Options Prices
Currently, No data available
---